Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.35 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | GMNN | O75496 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14289099 | 0.76 | HSP90AA1 (0.35) | HSP90AA1NPC1L3MBTL1PRMT5KDM4E | |
| SCHEMBL22762898 | 0.75 | GRM4 (0.33) | EGFRNPC1L3MBTL1KDM4ELMNA | |
| SCHEMBL22131166 | 0.74 | PRMT5 (0.41) | HSP90AA1NPC1L3MBTL1PRMT5KDM4E | |
| SCHEMBL20329008 | 0.74 | MEN1 (0.36) | KDM4EMAPTCCR1CCR5CCR8 | |
| SCHEMBL13454691 | 0.74 | HSP90AA1 (0.45) | EGFRHSP90AA1NPC1L3MBTL1PRMT5 | |
| SCHEMBL803121 | 0.72 | PI4KA (0.50) | EGFRNPC1L3MBTL1LMNATSHR | |
| SCHEMBL8585181 | 0.72 | MAPT (0.46) | EGFRHSP90AA1NPC1L3MBTL1KDM4E | |
| SCHEMBL10327466 | 0.71 | ALDH1A1 (0.40) | EGFRHSP90AA1NPC1L3MBTL1PRMT5 | |
| SCHEMBL12733330 | 0.71 | CCR1 (0.52) | HSP90AA1L3MBTL1KDM4EMAPTLMNA | |
| SCHEMBL22792600 | 0.70 | HSP90AA1 (0.34) | HSP90AA1NPC1L3MBTL1PRMT5KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787793-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230002361-A1 | 2H-INDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | BIOGEN MA INC. | 2023-01-05 | — | — | US | disclosed |
| US-11266643-B2 | Triaryl compounds for treatment of PD-L1 diseases | CHEMOCENTRYX, INC. (US) | 2022-03-08 | — | — | US | disclosed |
| US-11021467-B2 | Phosphatidylinositol 3-kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| WO-2020163193-A1 | BICYCLIC ETHER O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC. (US) | 2020-08-13 | — | — | WO | disclosed |
| US-10308639-B2 | Phosphatidylinositol 3-kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-10308644-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180179197-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| US-20180179197-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| US-20150361054-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2015-12-17 | — | — | US | disclosed |
| US-20150361095-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2015-12-17 | — | — | US | disclosed |
| US-20150307520-A1 | NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITIONS AND METHODS THEREOF | HUTCHISON MEDIPHARMA LTD (CN) | 2015-10-29 | — | — | US | disclosed |
| US-20150291593-A1 | NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITIONS AND METHODS | HUTCHISON MEDIPHARMA LTD (CN) | 2015-10-15 | — | — | US | disclosed |
| US-20110098305-A1 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | BAELL JONATHAN BAYLDON | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307520-A1 | NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITIONS AND METHODS THEREOF | PIK3C3, PIK3C2B, PIK3C2A | EGFR 1670/4885HSP90AA1 2191/4885NPC1 2926/4885 |
| US-10308639-B2 | Phosphatidylinositol 3-kinase inhibitors | PIK3CA, AKT3, AKT2 | EGFR 723/4885HSP90AA1 3257/4885NPC1 1252/4885 |
| US-20150361095-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3CA, AKT3, PIK3CD | EGFR 963/4885HSP90AA1 3383/4885NPC1 1786/4885 |
| US-20230002361-A1 | 2H-INDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | IRAK4, IRAK3, IRAK2 | EGFR 874/4885HSP90AA1 4076/4885NPC1 2601/4885 |
| US-20150361054-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3CA, AKT3, PIK3CB | EGFR 859/4885HSP90AA1 3348/4885NPC1 1543/4885 |
| US-20150291593-A1 | NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITIONS AND METHODS | PIK3C2B, PIK3C3, PIK3C2A | EGFR 1517/4885HSP90AA1 1642/4885NPC1 2442/4885 |
| US-11787793-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | EGFR 3005/4885HSP90AA1 662/4885NPC1 945/4885 |
| US-10308644-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | EGFR 3005/4885HSP90AA1 662/4885NPC1 945/4885 |
| US-20180179197-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | EGFR 3005/4885HSP90AA1 662/4885NPC1 945/4885 |
| US-20110098305-A1 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | BAX, API5, BCL2 | EGFR 3840/4885HSP90AA1 1304/4885NPC1 2292/4885 |
| US-11266643-B2 | Triaryl compounds for treatment of PD-L1 diseases | CD274, PDCD1, PDCD1LG2 | EGFR 1219/4885HSP90AA1 3761/4885NPC1 1417/4885 |
| US-11021467-B2 | Phosphatidylinositol 3-kinase inhibitors | PIK3CA, PIK3C2B, PIK3CB | EGFR 770/4885HSP90AA1 3401/4885NPC1 1544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.